AstraZeneca wins FDA nod for SGLT2 combo diabetes med; Novo hiring in NH for new hemophilia factory;

@FiercePharma: CEO-hunting Sanofi tried to tempt AstraZeneca's Soriot: Bloomberg. Article | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi says it doesn't not know why its flu strains grew slowly, holding up vax deliveries in U.S. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pfizer beats out Novartis with FDA MenB nod. FierceVaccines article | Follow @CarlyHFierce

> AstraZeneca ($AZN) won the FDA's blessing for its combination diabetes treatment Xigduo, which encompasses its new SGLT2 drug dapagliflozin and the standard therapy metformin. Release

> Novo Nordisk ($NVO) is staffing up in New Hampshire for a new facility that will turn out hemophilia treatments for the U.S. market. Release

> India's Cipla launched a cheaper copy of the Novartis ($NVS) respiratory drug Onbrez in its home market, and has asked the government to pull the Swiss drugmaker's patents on the product. Report

> AMAG Pharmaceuticals ($AMAG) reported $25.5 million in third-quarter revenue, most of which came from its anemia drug Feraheme. Report

> Fujifilm backed away from estimating how profitably its flu-fighting drug Avigan might be; the company is expanding production of the drug, which is earmarked to fight Ebola. Report

Medical Device News

@FierceMedDev: Ken Drazan of JNJ Innovation talks future of med tech. Editor's Corner | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Rating agencies likely to cut Medtronic's credit rating due to looming merger with Covidien. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Check out @FierceMedDev's list of the most influential women in the med tech industry here. Feature | Follow @EmilyWFierce

@MichaelGFierce: @HarvardResearch team uses stem cells to deliver toxic doses to #cancer cells. More | Follow @MichaelGFierce

> Chinese government urges hospitals to buy local devices. News

> Nintendo developing cloud-based sleep-monitoring device amid market growth. Story

> GE Healthcare opens first health tech incubator. Article

Biotech News

@FierceBiotech: ICYMI earlier this month, check out this year's Women in Biotech, featuring women at the top of their field. Feature | Follow @FierceBiotech

@JohnCFierce: If $SNY's board did turn to Soriot ($AZN) to try and recruit him for CEO, it shows they don't really know what they're doing. | Follow @JohnCFierce

@DamianFierce: Six of Cleveland Clinic's Top 10 Medical Innovations are drugs, and here's a bunch of words on them. Article | Follow @DamianFierce

@EmilyMFierce: Good read on Sarepta and the issue of compassionate use. More from Bloomberg BusinessWeek | Follow @EmilyMFierce

> Little Cortendo gains $11M for late-stage Cushing's study, hatches U.S. IPO plans. Story

> Bristol-Myers' nivolumab impresses once again--this time in crucial lung cancer study. Report

> Novo Nordisk walks back some U.S. optimism for its next-gen insulin. Article

Vaccines News

> South African trial renews hopes in failed HIV vaccine combo. More

> Dendreon's Provenge at the center of CMS insider trading probe. Item

> Pfizer beats out Novartis with FDA MenB nod. Story

> Ebola update: Novavax testing nanoparticle jab, Glaxo gets EMA's advice. More

> Novartis officially bows out of vaccines with flu sale to CSL. Article

Pharma Manufacturing News

> Turkish man sent to prison for smuggling fake Avastin into U.S. Item

> Novo hiring 90 workers for its new plant in New Hampshire. News

> More heat applied to Genentech CEO for supply-chain decision on cancer drugs. Report

> Lilly offers behind-the-scenes look at its decade-long tech transfer for TB drugs. Story

> Serum Institute of India to invest $160M in new plant. Article

And Finally... Google ($GOOG) is developing a pill to sniff out cancer, heart disease. Report

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.